FindTrial
Sign In

To study the molecular mechanism of Fuzheng anti-poison pill treatment of AIDS immune reconstructive imperfecta based on human CD4+T lymphocyte m6A methylation

To study the molecular mechanism of Fuzheng anti-poison pill treatment of AIDS immune reconstructive imperfecta based on human CD4+T lymphocyte m6A methylation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000306
Enrollment
Unknown
Registered
2025-02-17
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS immune reconstitution is incomplete

Interventions

AW group:placebo
FZ group:Fuzheng Anti-poison pill

Sponsors

Yunnan Institute of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: It meets the diagnostic criteria of AIDS and immune reconstitution insufficiency Chinese men and women aged 18-65; Agree to participate in the study.

Exclusion criteria

Exclusion criteria: Patients with severe diseases of cardiovascular system respiratory system digestive system blood system urinary system and nervous system were observed. Persons with severe mental illness; Pregnant or nursing women who have not recovered from serious trauma; Those who could not take medicine on time for other reasons during the observation period; Is participating in other researchers; Allergies people who are allergic to drugs used in the study.

Design outcomes

Primary

MeasureTime frame
CD4+ cell count;—

Countries

CHINA

Contacts

Public ContactWANG LI

Yunnan Institute of Traditional Chinese Medicine

wangli700519@163.com13769148882

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026